Active ingredientLisinoprilCat. No. P-L075-001CAS 76547-98-3Family · Pharmaceutical analytical standards
Lisinopril
An ACE inhibitor used for high blood pressure, heart failure and after heart attacks, patented in 1978 and approved in the United States in 1987; in 2023 it was the fourth most prescribed medicine in the US. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?Its name recalls lysine, the amino acid built into its structure: unlike almost all ACE inhibitors it is not a prodrug, and it is excreted unchanged in the urine.
Go to the active ingredient →Active ingredientLisinoprilCat. No. P-L075-001CAS 76547-98-3
Active ingredientLisinopril DihydrateCat. No. P-L075-002CAS 83915-83-7
Pharmacopoeial impurityLisinopril EP Impurity FCat. No. P-L075-003CAS 1132650-67-9
Pharmacopoeial impurityLisinopril EP Impurity ACat. No. P-L075-004CAS 1012-05-1
Pharmacopoeial impurityLisinopril EP Impurity CCat. No. P-L075-005CAS 328385-86-0
Pharmacopoeial impurityLisinopril EP Impurity C HClCat. No. P-L075-006
Pharmacopoeial impurityLisinopril EP Impurity DCat. No. P-L075-007CAS 219677-82-4
Pharmacopoeial impurityLisinopril EP Impurity D HClCat. No. P-L075-008
Pharmacopoeial impurityLisinopril EP Impurity ECat. No. P-L075-009CAS 85955-59-5
Pharmacopoeial impurityLisinopril EP Impurity GCat. No. P-L075-010CAS 1356839-89-8
Pharmacopoeial impurityLisinopril EP Impurity HCat. No. P-L075-011CAS 138247-43-5
Pharmacopoeial impurityLisinopril EP Impurity ICat. No. P-L075-012
Pharmacopoeial impurityLisinopril EP Impurity JCat. No. P-L075-013CAS 2566937-60-6
Isotopically labelledLisinopril-d5Cat. No. P-L075-014CAS 1356905-39-9
Isotopically labelledLisinopril-d5 SodiumCat. No. P-L075-015CAS 1356847-28-3
Isotopically labelledN-Nitroso Lisinopril-d5Cat. No. P-L075-016
NitrosamineN-Nitroso LisinoprilCat. No. P-L075-017CAS 519175-80-5
Impurity2,2,2-Trifluoroethyl formateCat. No. P-L075-018CAS 32042-38-9
Impurity2-Oxo-4-phenylbutanoic AcidCat. No. P-L075-019CAS 710-11-2
ImpurityLisinopril (8R,S)-DiketopiperazineCat. No. P-L075-020CAS 1092813-99-4
ImpurityLisinopril Butylamine Analog (Racemic)Cat. No. P-L075-021
ImpurityLisinopril DL-Alanine AnalogCat. No. P-L075-022
ImpurityLisinopril Formic acid AnalogCat. No. P-L075-023CAS 2764593-85-1
ImpurityLisinopril Impurity 1Cat. No. P-L075-024
ImpurityLisinopril Impurity 2Cat. No. P-L075-025
ImpurityLisinopril Impurity 3Cat. No. P-L075-026
ImpurityLisinopril Impurity 4Cat. No. P-L075-027
ImpurityLisinopril Impurity 5Cat. No. P-L075-028CAS 488760-32-3
ImpurityLisinopril Impurity 6Cat. No. P-L075-030
ImpurityLisinopril Impurity 7Cat. No. P-L075-031
ImpurityLisinopril Impurity 8Cat. No. P-L075-033
ImpurityLisinopril Impurity 9Cat. No. P-L075-034
ImpurityLisinopril Impurity 10Cat. No. P-L075-035
ImpurityLisinopril Impurity 11Cat. No. P-L075-036CAS 103300-91-0
ImpurityLisinopril Impurity 12Cat. No. P-L075-037
ImpurityLisinopril Impurity 13Cat. No. P-L075-038
ImpurityLisinopril Impurity 14Cat. No. P-L075-039
ImpurityLisinopril Impurity 15Cat. No. P-L075-040
ImpurityLisinopril Impurity 16Cat. No. P-L075-041
ImpurityLisinopril Impurity 17Cat. No. P-L075-042
ImpurityLisinopril Impurity 18Cat. No. P-L075-043
ImpurityLisinopril Impurity HCat. No. P-L075-044
ImpurityN,N'-bis-trifluoroacetyl-L-lysineCat. No. P-L075-045CAS 329-53-3
ImpurityN-Carboxymethyl LisinoprilCat. No. P-L075-047
ImpurityN-Formyl LisinoprilCat. No. P-L075-048
ImpurityLisinopril Impurity 19Cat. No. P-L075-049CAS 116169-90-5
ImpurityN2-(2,2,2-Trifluoroacetyl)-L-lysineCat. No. P-L075-050CAS 21761-08-0
ImpurityLisinopril Impurity 20Cat. No. P-L075-051CAS 2389-60-8
ImpurityN6-(2,2,2-trifluoroacetyl)-L-lysineCat. No. P-L075-052CAS 10009-20-8No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
Reference substanceLisinopril dihydrate CRSEDQM code L0702000Family LisinoprilImpurityLisinopril impurity F CRSEDQM code Y0001234Family LisinoprilNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.